March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
8 citations
,
April 2009 in “International journal of oncology” Hair follicle cells resist turning into skin cells.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
16 citations
,
March 2021 in “Frontiers in cell and developmental biology” A new method using Y-27632 improves the growth and quality of human hair follicle stem cells for tissue engineering and therapy.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
2 citations
,
August 2023 in “Molecules” SH-340 may improve skin barrier and help treat atopic dermatitis.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
50 citations
,
February 2007 in “The Journal of Pathology” Somatic BHD mutations are rare in Japanese renal tumors.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the reference drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
The balance between cell renewal and differentiation controls the growth of cancerous cells in mouse skin.
April 2021 in “Journal of Investigative Dermatology” Stem cells control their future role by changing ERK signal timing, affecting tissue regeneration and cancer.
November 2023 in “Cell Proliferation” A protein from fat-derived stem cells, DKK1, is linked to hair loss and blocking it may help treat alopecia areata.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
91 citations
,
April 2006 in “PubMed” EGFR-targeting cancer drugs can cause skin rashes and other side effects.
January 2019 in “Proceedings for Annual Meeting of The Japanese Pharmacological Society” Nε-(carboxymethyl) lysine delays hair growth by blocking a key protein.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
25 citations
,
April 1985 in “Journal of Investigative Dermatology” 219 citations
,
July 1995 in “PubMed” Keratinocyte growth factor promotes hair growth and reduces hair loss from chemotherapy.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the standard drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.